Myriad Genetics

Counsyl is a health technology company specializing in DNA screening for individuals and families. Its services aim to provide critical health information that can influence important decisions regarding behavior, prevention, and preparedness for future health challenges. By leveraging advanced technology, including custom-built robotics and a team of scientists and engineers, Counsyl processes blood and saliva samples with high precision and efficiency. The company has screened over 500,000 patients and collaborated with more than 6,000 healthcare professionals, striving to make DNA screening accessible to a broad audience. Counsyl’s innovative approach has earned recognition, including the Wall Street Journal’s Innovation Award for Medicine, and its Family Prep Screen has significantly aided individuals in understanding crucial genetic information prior to childbearing. The platform has expanded its offerings to include informed pregnancy and cancer screening, emphasizing the integration of sophisticated technology in real-time communication of medical results between patients and healthcare providers.

Assurex Health is a personalized medicine company dedicated to helping clinicians determine the right medication for individual patients with medical conditions. Assurex Health’s proprietary Genesight® technology is based on pharmacogenomics – the study of the genetic factors that influence an individual’s response to drug treatments – as well as evidence-based medicine and clinical pharmacology.

Sividon Diagnostics GmbH develops a portfolio of treatment-related diagnostic tests. The company specializes in molecular tumor diagnostics. Its portfolio includes ImmunoPredict biomarker test. The company was founded in 2011 and is based in Cologne, Germany. Sividon Diagnostics GmbH operates as a subsidiary of Myriad Services GmbH.

Privatklinik Dr. Robert Schindlbeck GmbH & Co. Kg, a subsidiary of Myriad Services GmbH, specializes in delivering health care services. The clinic is dedicated to providing comprehensive medical care, focusing on patient-centered treatment and individualized health solutions. Its offerings are designed to meet the diverse needs of patients, ensuring high standards of care in a private medical setting.

Crescendo Bioscience, Inc. is a molecular diagnostics company based in South San Francisco, California, specializing in the development of quantitative blood tests for autoimmune and inflammatory diseases, particularly rheumatoid arthritis (RA). Established in 2002, the company offers diagnostic, prognostic, staging, therapy selection, and monitoring tools designed to assist rheumatologists in managing patient care. One of its key products is Vectra DA, a standardized multi-biomarker blood test validated to evaluate disease activity in RA. By providing objective and quantitative molecular tests, Crescendo Bioscience aims to enhance clinical insights for rheumatologists and improve patient outcomes.

RainDance Technologies, Inc. specializes in developing genomic tools for non-invasive liquid biopsy applications, focusing on the research, early detection, and treatment of cancer and other diseases. The company offers a range of products, including the RainDrop digital polymerase chain reaction platform, which utilizes picoliter-sized droplets for the multiplex detection of various genetic materials such as DNA and RNA. Additionally, it provides the RainDrop Plus system for next-generation sequencing (NGS) amplicon enrichment and the ThunderStorm automated NGS content enrichment solution, which enhances the processing of samples and data quality. RainDance also offers targeted NGS panels like ThunderBolts, aimed at profiling cancer mutations and understanding myeloid disorders. The company serves major research institutions and laboratories globally through a network of sales representatives and distributors. Founded in 2004 and based in Billerica, Massachusetts, RainDance Technologies operates as a subsidiary of Bio-Rad Laboratories, Inc.

Crescendo Bioscience, Inc. is a molecular diagnostics company based in South San Francisco, California, specializing in the development of quantitative blood tests for autoimmune and inflammatory diseases, particularly rheumatoid arthritis (RA). Established in 2002, the company offers diagnostic, prognostic, staging, therapy selection, and monitoring tools designed to assist rheumatologists in managing patient care. One of its key products is Vectra DA, a standardized multi-biomarker blood test validated to evaluate disease activity in RA. By providing objective and quantitative molecular tests, Crescendo Bioscience aims to enhance clinical insights for rheumatologists and improve patient outcomes.

Rules-Based Medicine (RBM), the world's leading multiplexed biomarker testing laboratory, provides comprehensive protein biomarker products and services based on its Multi-Analyte Profiling (MAP) technology platform. RBM's biomarker testing service provides pre-clinical and clinical researchers with reproducible, quantitative, multiplexed immunoassay data for hundreds of proteins in a cost-effective manner, from a small sample volume and from multiple species. Their biomarker testing laboratory is CLIA certified and supports GLP studies.

Javelin Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the research, development, and commercialization of products for the pain management market primarily in the United States and Europe. Its products focus on treating various pain disorders ranging from acute and episodic moderate-to-severe pain associated with breakthrough cancer pain, post-operative pain, post-trauma pain (orthopedic injury pain), procedural pain, and burn pain. The company's Dyloject (injectable diclofenac) received approval for marketing to treat post-operative pain in the United Kingdom and was licensed to Therabel Pharma N.V. for commercialization in the European Union and certain other countries outside the United States. Its products in the Phase 3 development stage in the U.S. include Dyloject (diclofenac sodium injectable), an injectable formulation of diclofenac and a prescription nonsteroidal anti-inflammatory drug that is used to treat post-operative pain due to its combination of effectiveness and tolerability; Ereska (intranasal ketamine), a proprietary nasal formulation; and Rylomine (intranasal morphine) for treatment of acute moderate-to-severe pain, including breakthrough pain. Javelin Pharmaceuticals has license agreements with Shimoda Biotech, Ltd. to develop and commercialize products related to a proprietary formulation of the injectable delivery of diclofenac; and West Pharmaceutical Services, Inc. to develop and commercialize intranasal morphine for the transmucosal delivery of morphine to humans and animals for the treatment of pain. The company was founded in 1998 and is based in Cambridge, Massachusetts.

NaturNorth Technologies is a pioneering biotech discovery and development company focused on efficient isolation of the life improving bioactive compounds found in birch bark.